Back to Clinical Trials
Phase 1Recruiting

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Sponsored by A2 Biotherapeutics Inc.

About this study

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

This is a seamless phase 1/2, multi-center, open-label study that enrolls adults with recurrent unresectable, locally advanced, or metastatic (considered non-curative) CRC, NSCLC, PANC, OVCA, MESO or other solid tumors with MSLN expression. Subjects must be germline HLA-A\*02 heterozygous, with tumors that express MSLN and have lost HLA-A\*02 expression. This study has two arms: Arm 1 is a study of A2B694 and Arm 2 is a study of A2B543. The purpose of Phase 1 of this study is to determine the safety and the optimal dose of the Tmod products (after PCLD) in participants with solid tumor disease. The purpose of Phase 2 of this study is to determine the further safety and efficacy (how well it treats the solid tumor disease) of the Tmod products. The treatment available for these cancers an…

Where this study is enrolling (10)

Show all 10 locations
Who can participate

Inclusion criteria

  • ✓Key Inclusion Criteria:
  • ✓1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy
  • ✓2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.
  • ✓3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol
  • ✓4. Has adequate organ function as described in the protocol
  • ✓5. ECOG performance status of 0 to 1
  • ✓6. Life expectancy of ≥3 months
  • ✓7. Willing to comply with study schedule of assessments including long term safety follow up

Exclusion criteria

  • ✕1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative
  • ✕2. Prior allogeneic stem cell transplant
  • ✕3. Prior solid organ transplant
  • ✕4. MESO with pleural involvement extending into the peritoneum
  • ✕5. Cancer therapy within 3 weeks or 3 half lives of infusion
  • ✕6. Radiotherapy within 28 days of infusion
  • ✕7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months
  • ✕8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated
  • ✕9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year
  • ✕10. Requires supplemental home oxygen
  • ✕11. Females of childbearing potential who are pregnant or breastfeeding
  • ✕12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.